Bluebird Bio shares are trading higher after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $6 to $10.
Portfolio Pulse from Benzinga Newsdesk
Bluebird Bio's stock has been upgraded from Neutral to Buy by B of A Securities, which also raised its price target from $6 to $10.
July 19, 2023 | 2:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bluebird Bio's stock has been upgraded by B of A Securities, with a raised price target, which could lead to increased investor interest.
The upgrade from B of A Securities is a positive signal for Bluebird Bio. It indicates increased confidence in the company's prospects, which could attract more investors and potentially drive the stock price up. The raised price target also suggests that the stock is undervalued at its current price, which could further stimulate buying interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100